Nearly half (48%) of patients undergoing anticancer therapies for gynecological tumors experience early cardiovascular complications during treatment, while 30% suffer from long-term cardiac sequelae up to 13 years later.
What are the cardiovascular toxicities associated with various anticancer therapies in patients with gynecological tumors?
This review highlights the diverse and significant cardiovascular toxicities associated with modern anticancer therapies for gynecological tumors, emphasizing the need for cardio-oncology monitoring.
Effect estimate: RR 19.01 (95% CI 7.77-46.55)
p-value: p=<0.00001
The continuous advancement in the management of gynecological cancers has contributed to improved patient survival. Nevertheless, cardiovascular toxicity resulting from anti-tumor treatments has emerged as a significant threat to long-term quality of life and non-cancer-related mortality. This review systematically elaborates on the cardiovascular risk of the conventional treatment of gynecological tumor viz chemotherapy, targeted therapy, immunotherapy, endocrine therapy and radiotherapy. The molecular mechanisms of each therapy will also be discussed, including oxidative stress, mitochondrial dysfunction, endothelial injury and immune-mediated inflammation. Additionally, we outline the major risk factors associated with anticancer therapy related cardiovascular toxicity and give an insight into monitoring, diagnosis and management of complications.
Yang et al. (Tue,) conducted a review in gynecological cancers. various anticancer therapies was evaluated on incidence of cardiac toxicity in patients receiving chemotherapy and targeted therapy (RR 19.01, 95% CI 7.77-46.55, p=<0.00001). Nearly half (48%) of patients undergoing anticancer therapies for gynecological tumors experience early cardiovascular complications during treatment, while 30% suffer from long-term cardiac sequelae up to 13 years later.